ACAD - ACADIA PHARMACEUTICALS INC

14.73
-0.100   -0.679%

Share volume: 957,584
Last Updated: 04-25-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$14.83
-0.10
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
68%
Profitability 74%
Dept financing 30%
Liquidity 75%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.75%
1 Month
-13.71%
3 Months
-19.95%
6 Months
-0.07%
1 Year
-13.86%
2 Year
-30.94%
Key data
Stock price
$14.73
P/E Ratio 
13.48
DAY RANGE
$14.47 - $14.83
EPS 
$1.37
52 WEEK RANGE
$13.40 - $20.68
52 WEEK CHANGE
-$13.86
MARKET CAP 
3.053 B
YIELD 
N/A
SHARES OUTSTANDING 
165.876 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.34
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,337,533
AVERAGE 30 VOLUME 
$1,746,029
Company detail
CEO: Stephen R. Davis
Region: US
Website: acadia-pharm.com
Employees: 510
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Recent news
loading